0 adjuvant folfiri +/- cetuximab in patients with resected stage iii colon cancer ncctg intergroup...
TRANSCRIPT
1
Adjuvant FOLFIRI +/- Cetuximab in Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Patients with Resected Stage III
Colon CancerColon CancerNCCTG Intergroup Phase III Trial NCCTG Intergroup Phase III Trial
N0147N0147
Adjuvant FOLFIRI +/- Cetuximab in Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Patients with Resected Stage III
Colon CancerColon CancerNCCTG Intergroup Phase III Trial NCCTG Intergroup Phase III Trial
N0147N0147
Jocelin Huang, Daniel J Sargent, Michelle R Jocelin Huang, Daniel J Sargent, Michelle R Mahoney, Stephen N Thibodeau, Thomas C Mahoney, Stephen N Thibodeau, Thomas C Smyrk, Frank A Sinicrope, Garth D Nelson, Smyrk, Frank A Sinicrope, Garth D Nelson,
Steven R AlbertsSteven R Alberts
ASCO GI Cancers SymposiumASCO GI Cancers Symposium
January 22, 2011January 22, 2011
Jocelin Huang, Daniel J Sargent, Michelle R Jocelin Huang, Daniel J Sargent, Michelle R Mahoney, Stephen N Thibodeau, Thomas C Mahoney, Stephen N Thibodeau, Thomas C Smyrk, Frank A Sinicrope, Garth D Nelson, Smyrk, Frank A Sinicrope, Garth D Nelson,
Steven R AlbertsSteven R Alberts
ASCO GI Cancers SymposiumASCO GI Cancers Symposium
January 22, 2011January 22, 2011
2
DisclosuresDisclosures
NCI provided primary support for the NCI provided primary support for the trial trial
Additional grants to support the trial Additional grants to support the trial and its translational components and its translational components received from:received from:• Bristol-Myers SquibbBristol-Myers Squibb• ImClone SystemsImClone Systems• sanofi-aventissanofi-aventis• PfizerPfizer
NCI provided primary support for the NCI provided primary support for the trial trial
Additional grants to support the trial Additional grants to support the trial and its translational components and its translational components received from:received from:• Bristol-Myers SquibbBristol-Myers Squibb• ImClone SystemsImClone Systems• sanofi-aventissanofi-aventis• PfizerPfizer
3
Background: Irinotecan in Adjuvant Therapy
Background: Irinotecan in Adjuvant Therapy
• Irinotecan has demonstrated antitumor activity against metastatic colorectal cancer used alone or with 5-FU/LV
• However, in resected stage III no statistically significant difference demonstrated in DFS and OS between FOLFIRI and 5FU/LV
• Irinotecan has demonstrated antitumor activity against metastatic colorectal cancer used alone or with 5-FU/LV
• However, in resected stage III no statistically significant difference demonstrated in DFS and OS between FOLFIRI and 5FU/LV
4
Clinical Trials Evaluating Addition of Irinotecan to 5FU/LV in Resected CRC: No Benefit in DFS and OS
Clinical Trials Evaluating Addition of Irinotecan to 5FU/LV in Resected CRC: No Benefit in DFS and OS
PETACC-3 (FOLFIRI)• 3,018 patients with resected
stage II/III colon cancerDFS P=0.106OS P=0.09
ACCORD2 (FOLFIRI)• 400 patients with resected
high-risk stage III colon cancer (N2 or N1 with occlusion/perforation)DFS P=0.92OS P=0.99
CALGB 89803 (IFL)• 1,264 patients with resected
stage III colon cancerDFS P=0.85OS P=0.74
PETACC-3 (FOLFIRI)• 3,018 patients with resected
stage II/III colon cancerDFS P=0.106OS P=0.09
ACCORD2 (FOLFIRI)• 400 patients with resected
high-risk stage III colon cancer (N2 or N1 with occlusion/perforation)DFS P=0.92OS P=0.99
CALGB 89803 (IFL)• 1,264 patients with resected
stage III colon cancerDFS P=0.85OS P=0.74
LV/5-FU2
FOLFIRI
12 cycles planned
R
5
N0147: Initial Design in 2001N0147: Initial Design in 2001
Planned Accrual: 3750
FOLFIRI
5-FU 400 mg/m2 + Bolus CPT-11 180 mg/m2 + LV 400 mg/m2 & 5-FU 2,400 mg/m2 over 46 hrs Q 2 w
mFOLFOX6
5-FU 400 mg/m2 + Oxaliplatin 85 mg/m2 + LV 400 mg/m2 & 5-FU 2,400 mg/m2 over 26 hrs Q 2 w
mFOLFOX6 FOLFIRI
Planned Accrual: 3750
FOLFIRI
5-FU 400 mg/m2 + Bolus CPT-11 180 mg/m2 + LV 400 mg/m2 & 5-FU 2,400 mg/m2 over 46 hrs Q 2 w
mFOLFOX6
5-FU 400 mg/m2 + Oxaliplatin 85 mg/m2 + LV 400 mg/m2 & 5-FU 2,400 mg/m2 over 26 hrs Q 2 w
mFOLFOX6 FOLFIRI
RR
6
N0147: First Design ChangeN0147: First Design Change
• Addition of Cetuximab Sept-04• 6 arm design
• FOLFIRI +/- cetuximab
• FOLFOX +/- cetuximab
• FOLFOX FOLFIRI +/- cetuximab
• Addition of Cetuximab Sept-04• 6 arm design
• FOLFIRI +/- cetuximab
• FOLFOX +/- cetuximab
• FOLFOX FOLFIRI +/- cetuximab
R
7
N0147: FOLFIRI +/- CetuximabN0147: FOLFIRI +/- Cetuximab
• Addition of Cetuximab Sept-04• 6 arm design
• FOLFIRI +/- Cetuximab (Cmab)
• FOLFOX +/- Cmab
• FOLFOX FOLFIRI +/- Cmab
• Addition of Cetuximab Sept-04• 6 arm design
• FOLFIRI +/- Cetuximab (Cmab)
• FOLFOX +/- Cmab
• FOLFOX FOLFIRI +/- Cmab
R
8
Goals for N0147 FOLFIRI +/- Cmab Arms
Goals for N0147 FOLFIRI +/- Cmab Arms
• Primary• Compare disease free survival (DFS)
between FOLFIRI and FOLFIRI + Cmab in patients with wild-type (WT) K-ras and mutant (MT) K-ras
• Secondary• Compare overall survival (OS) in the two
groups • Assess toxicities resulting from the
addition of Cmab
• Primary• Compare disease free survival (DFS)
between FOLFIRI and FOLFIRI + Cmab in patients with wild-type (WT) K-ras and mutant (MT) K-ras
• Secondary• Compare overall survival (OS) in the two
groups • Assess toxicities resulting from the
addition of Cmab
9
K-ras AssessmentK-ras Assessment
K-ras Testing: • Centralized testing performed in a
CLIA approved lab at Mayo Clinic• DxS Assay using the Roche
LightCycler 480 platform• 99.2% of samples provided
interpretable result
K-ras Testing: • Centralized testing performed in a
CLIA approved lab at Mayo Clinic• DxS Assay using the Roche
LightCycler 480 platform• 99.2% of samples provided
interpretable result
10
Eligibility for N0147Eligibility for N0147
• Inclusion• Completely resected colon
adenocarcinoma• > 1 pathologically confirmed lymph
node identified• Age > 18 years• Acceptable liver and kidney
function• Standard hematologic parameters
• Inclusion• Completely resected colon
adenocarcinoma• > 1 pathologically confirmed lymph
node identified• Age > 18 years• Acceptable liver and kidney
function• Standard hematologic parameters
11
Eligibility for N0147Eligibility for N0147
• Exclusion• Evidence of metastatic disease
• En bloc resection for locally advanced disease allowed
• Prior chemotherapy or radiation for colon cancer
• Prior or concurrent malignancies within 5 years
• Clinically significant peripheral neuropathy
• Exclusion• Evidence of metastatic disease
• En bloc resection for locally advanced disease allowed
• Prior chemotherapy or radiation for colon cancer
• Prior or concurrent malignancies within 5 years
• Clinically significant peripheral neuropathy
12
N0147: FOLFIRI +/- CmabN0147: FOLFIRI +/- Cmab
ResectedResectedStage 3 Stage 3 Colon Colon CancerCancer
(N = 146)(N = 146)
RRAANNDDOOMMIIZZEE
FOLFIRI (12 cycles)FOLFIRI (12 cycles)• Irinotecan 180 mg/mIrinotecan 180 mg/m22
• LV 400 mg/mLV 400 mg/m22 & & • 5-FU 2,400 mg/m5-FU 2,400 mg/m22 over 46 hrs over 46 hrs every 2 weeksevery 2 weeks
FOLFIRI + CetuximabFOLFIRI + Cetuximab (12 cycles)(12 cycles)• FOLFIRI FOLFIRI • Cetuximab days 1,8 Cetuximab days 1,8 - 400 mg/m- 400 mg/m22 loading dose loading dose - 250 mg/m- 250 mg/m22 weekly weekly
13
Final Study PopulationFinal Study Population
• 156 patients accrued to arms B (111) and E (45)
• 5 cancels (2-B, 3-E) did not receive treatment - removed from analysis
• 7 ineligible patients (4-B, 3-E)
• 2 ineligible patients (1-B, 1-E) included in analysis because deemed ineligible due to time delay for starting treatment
• Other 5 ineligible patients (3-B, 2-E) removed from analysis
• Final: 146 patients (106-B, 40-E) included in analysis
• 156 patients accrued to arms B (111) and E (45)
• 5 cancels (2-B, 3-E) did not receive treatment - removed from analysis
• 7 ineligible patients (4-B, 3-E)
• 2 ineligible patients (1-B, 1-E) included in analysis because deemed ineligible due to time delay for starting treatment
• Other 5 ineligible patients (3-B, 2-E) removed from analysis
• Final: 146 patients (106-B, 40-E) included in analysis
14
Patient Characteristic FOLFIRI(N = 106)
FOLFIRI+Cmab(N = 40)
Median (range) Age (years) 57 (25-82) 59 (30-82)
Gender Female Male
47%53%
45%55%
Race Caucasian African American Other
90%6%4%
85%8%7%
Median (range) Follow-up (months)
N = 7960 (3-72)
N = 3759 (2-67)
15
Tumor Characteristic FOLFIRI(N=106)
FOLFIRI+Cmab(N=40)
Bowel Obstruction Yes No
14%86%
10%90%
Bowel Perforation Yes No
8%92%
5%95%
Histology High Low
23%77%
25%75%
Lymph Node Involvement 1 - 3 > 3
65%35%
65%35%
T Stage T1 or T2 T3 T4
16%70%14%
12%78%10%
16
K-ras mutation status
FOLFIRI(N=106)
FOLFIRI + Cmab(N=40)
Wild-type Mutant Missing
65%31%4%
65%33%2%
17
Disease-free Survival: WT-Kras (n=95)
Disease-free Survival: WT-Kras (n=95)
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60
Time (Months)
% A
liv
e a
nd
Dis
ea
se
Fre
e
FOLFIRI
FOLFIRI + C225
FOLFOX: 75.8%
FOLFOX + C225: 72.3%
ArmArm 3 Year Rates 3 Year Rates
(95% CI)(95% CI)
HR HR
(95% CI)(95% CI)
P-valueP-value
FOLFIRIFOLFIRI
N=69N=69
69.8%69.8%
(60%-82%)(60%-82%)
0.310.31
(0.09-(0.09-1.03)1.03)
0.040.04
FOLFIRI + C225FOLFIRI + C225
N=26N=26
92.3%92.3%
(83%-100%)(83%-100%)
18
Disease-free Survival: MT-Kras (n=46)
Disease-free Survival: MT-Kras (n=46)
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60
Time (Months)
% A
liv
e a
nd
Dis
ea
se
Fre
e
FOLFIRI
FOLFIRI + C225
FOLFOX: 67.2%
FOLFOX + Cmab: 64.2%
ArmArm 3 Year Rates 3 Year Rates
(95% CI)(95% CI)
HR HR
(95% CI)(95% CI)
P-valueP-value
FOLFIRIFOLFIRI
N=33N=33
56.3%56.3%
(41%-76%)(41%-76%)
0.450.45
(0.13-(0.13-1.53)1.53)
0.190.19
FOLFIRI + C225FOLFIRI + C225
N=13N=13
82.5%82.5%
(63%-100%)(63%-100%)
19
Disease-free Survival (n=146)Disease-free Survival (n=146)
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60
Time (Months)
% A
live
an
d D
isea
se F
ree
FOLFIRI
FOLFIRI + C225
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60
Time (Months)
% A
live
an
d D
isea
se F
ree
FOLFIRI
FOLFIRI + C225
FOLFOX: 75.8%
FOLFOX + Cmab: 72.3%
ArmArm 3 Year Rates 3 Year Rates
(95% CI)(95% CI)
HR HR
(95% CI)(95% CI)
P-valueP-value
FOLFIRIFOLFIRI
N=106N=106
66.7%66.7%
(58%-77%)(58%-77%)
0.440.44
(0.20-(0.20-0.97)0.97)
0.040.04
FOLFIRI + C225FOLFIRI + C225
N=40N=40
86.6%86.6%
(76%-98%)(76%-98%)
20
Overall Survival: WT-Kras (n=95)
Overall Survival: WT-Kras (n=95)
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60 72
Time (Months)
% A
live
FOLFIRI
FOLFIRI + C225
ArmArm 3 Year Rates 3 Year Rates
(95% CI)(95% CI)
HR HR
(95% CI)(95% CI)
P-valueP-value
FOLFIRIFOLFIRI
N=69N=69
85.2%85.2%
(77%-94%)(77%-94%)
0.340.34
(0.08-(0.08-1.48)1.48)
0.130.13
FOLFIRI + C225FOLFIRI + C225
N=26N=26
92.0%92.0%
(82%-100%)(82%-100%)
FOLFOX: 87.8%
FOLFOX + Cmab: 83.9%
21
Overall Survival: MT-Kras (n=46)
Overall Survival: MT-Kras (n=46)
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60 72
Time (Months)
% A
live
FOLFIRI
FOLFIRI + C225
ArmArm 3 Year Rates 3 Year Rates
(95% CI)(95% CI)
HR HR
(95% CI)(95% CI)
P-valueP-value
FOLFIRIFOLFIRI
N=33N=33
80.6%80.6%
(68%-96%)(68%-96%)
0.220.22
(0.03-(0.03-1.73)1.73)
0.120.12
FOLFIRI + C225FOLFIRI + C225
N=13N=13
90.9%90.9%
(75%-100%)(75%-100%)
22
Overall Survival (n=146)Overall Survival (n=146)
0
10
20
30
40
50
60
70
80
90
100
0 12 24 36 48 60 72
Time (Months)
% A
live
FOLFIRI
FOLFIRI + C225
FOLFOX: 87.8%
FOLFOX + Cmab: 83.9%
ArmArm 3 Year Rates 3 Year Rates
(95% CI)(95% CI)
HR HR
(95% CI)(95% CI)
P-valueP-value
FOLFIRIFOLFIRI
N=106N=106
84.4%84.4%
(78%-92%)(78%-92%)
0.300.30
(0.09-(0.09-1.00)1.00)
0.040.04
FOLFIRI + C225FOLFIRI + C225
N=40N=40
91.8%91.8%
(83%-100%)(83%-100%)
23
Toxicity – Grade 3-4Toxicity – Grade 3-4
FOLFIRI FOLFIRI + Cmab
Neutropenia 14% 10%Febrile Neutropenia 2% 3%Acne 0% 18%Nausea 10% 0%Diarrhea 14% 15%Paresthesias 0% 10%Infarction 0% 8%Overall 53% 68%
24
Reasons for DiscontinuationReasons for Discontinuation
Reason FOLFIRI FOLFIRI + Cmab
Completion 79% 70%
Refusal 8% 13%
Adverse Event 8% 18%
Other 6% 0%
25
ConclusionsConclusionsConclusionsConclusions• Adjuvant FOLFIRI resulted in a 3-year Adjuvant FOLFIRI resulted in a 3-year
DFS lower than that expected for DFS lower than that expected for FOLFOXFOLFOX
• Trends for improved DFS and OS Trends for improved DFS and OS with the addition of Cmab were with the addition of Cmab were observed in patients with resected observed in patients with resected stage III colon cancer patients, stage III colon cancer patients, regardless of KRAS statusregardless of KRAS status
• Possible different synergistic effect Possible different synergistic effect between FOLFIRI and Cmab than between FOLFIRI and Cmab than with FOLFOX and Cmabwith FOLFOX and Cmab
• Adjuvant FOLFIRI resulted in a 3-year Adjuvant FOLFIRI resulted in a 3-year DFS lower than that expected for DFS lower than that expected for FOLFOXFOLFOX
• Trends for improved DFS and OS Trends for improved DFS and OS with the addition of Cmab were with the addition of Cmab were observed in patients with resected observed in patients with resected stage III colon cancer patients, stage III colon cancer patients, regardless of KRAS statusregardless of KRAS status
• Possible different synergistic effect Possible different synergistic effect between FOLFIRI and Cmab than between FOLFIRI and Cmab than with FOLFOX and Cmabwith FOLFOX and Cmab
26
AcknowledgmentsAcknowledgmentsAcknowledgmentsAcknowledgments• All of the participating patients
• Collaboration with North American groups
• Support of NCI, Bristol-Myers Squibb, sanofi-aventis, ImClone, and Pfizer
• Study team
• All of the participating patients
• Collaboration with North American groups
• Support of NCI, Bristol-Myers Squibb, sanofi-aventis, ImClone, and Pfizer
• Study team